Seattle Genetics, Astellas Announce Phase 1 Bladder Cancer Trial Results

-Study Met Outcomes for Safety and 71 Percent of Patients with Locally Advanced or Metastatic Urothelial (Bladder) Cancer Had a Confirmed Response –

– Findings Presented Today at an Oral Session at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona –

Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced initial results from the phase 1 clinical trial EV-103. Forty-five patients were evaluated for safety with the combination of the investigational agent enfortumab vedotin and the immune therapy pembrolizumab in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy. The study met outcome measures for safety and exhibited encouraging clinical activity for this platinum-free combination in a first-line setting. The data will be presented during an oral session today at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain (Abstract #901O).

Enfortumab vedotin is a first-in-class antibody drug conjugate (ADC) that targets Nectin-4, a protein present on almost all urothelial tumor cells and associated with cancer formation.

https://www.marketscreener.com/SEATTLE-GENETICS-INC-10808/news/Seattle-Genetics-and-Astellas-Announce-Results-from-Phase-1-Trial-of-Investigational-Agent-Enfortu-29273851/